Edinburgh Marathon 2026
Held annually since 1982, the race begins in the city centre, before moving out of Edinburgh into East Lothian and finishes at Musselburgh in East Lothian. Are you ready to run for Retina UK?
Search
Search results
jCyte have released additional preclinical data regarding jCell
jCyte have released additional preclinical data regarding jCell
Renewed Momentum for XLRP: MeiraGTx Targets Rapid Approval Path for bota-vec following reacquisition from Johnson and Johnson
It has recently been announced that Meira-GTx, who originally developed bota-vec and collaborated with J&J during its early clinical trials, have entered into an asset purchase agreement with J&J to acquire bota-vec and progress the program towards global regulatory filings for approval.
Progress in Charles Bonnet Syndrome (CBS) research
We recently received an update on the latest research into Charles Bonnet Syndrome from Dr Jasleen Jolly as part of a Retina UK podcast about visual hallucinations.
Webinar: Michael Gilhooley, Optogenetics
This session will introduce the technique of optogenetics and its potential for development into a treatment for IRDs.
Meet a Researcher: Jing Yu
Jing Yu is a Research Assistant at the Nuffield Department of Clinical Neurosciences at the John Radcliffe Hospital in Oxford.
Meet a Researcher: Tomasz Tomkiewicz
Tomasz Tomkiewicz is undertaking a PhD studentship funded by Retina UK and The Macular Society.
Research round-up, spring 2023
Progress towards treatments for inherited retinal conditions continues to gather pace and there’s been lots going on in the last few months, with more and more approaches being explored. This round-up gives a flavour of the variety of developments, including plenty that are not specific to a particular genetic fault.
Our commitment to lived experience employment
In April 2022 we joined with another seven leading sight loss organisations to make a public commitment to increasing the number of blind and partially sighted people employed within our sector, including at senior management level.
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.